NEW YORK, May 22, 2020 /PRNewswire/ --
L-Carnitine Market to 2027 - Europe Analysis and Forecast-Covid-19
Impact and Analysis-by Process (Chemical Synthesis, Bioprocess);
Product (Food Grade, Pharmaceutical Grade, Feed Grade); Application
(Animal Feed, Healthcare Products, Functional Drinks, Medicines),
and Country
Read the full report:
https://www.reportlinker.com/p05894542/?utm_source=PRN
The L-Carnitine market was valued at US$
47.1 million in 2018 and is projected to reach US$ 72.7 million by 2027; it is expected to grow
at a CAGR of 4.9% from 2019 to 2027.
L-Carnitine is a naturally occurring compound in human and animal
bodies; it plays an important role of shuttling fatty acids to and
fro in the cells to produce energy.It is produced in the liver and
kidneys.
However, certain individuals are unable to produce or synthesize
required amount of L-Carnitine owing to genetic conditions or
defects.Such individuals suffer from primary and secondary
L-Carnitine deficiency.
The US Food and Drug Administration (FDA) has approved the use of
oral and intravenous (IV) L-Carnitine for treating primary and
secondary Carnitine deficiency.L-Carnitine is today commercially
advertised as nutritional supplements to enhance exercise
performance and promote weight loss.
It is also approved to treat Carnitine deficiencies in patients at
the end stage of renal diseases, undergoing hemodialysis.. Besides
its uses in human nutrition, L-Carnitine is also used as an
additive in animal feed formulations. It is used in the poultry
industry to increase egg production and improve egg
hatchability.
The L-Carnitine market, based on product, is segmented into food
grade, pharmaceutical grade, and feed grade.In 2018, the food grade
segment accounted for the largest share of the Europe L-Carnitine
market, whereas the pharmaceutical grade segment is expected to
register the fastest CAGR during the forecast period.
L-Carnitine mainly carries out two functions—the first is the
transportation of fatty acids into mitochondria, where they are
burned and oxidized to produce energy, and the rest is the
transportation of waste and toxic compounds out of mitochondria,
thus preventing unwanted substances getting accumulated in the
body.The consumption of L-Carnitine assists in the treatment of
heart conditions such as heart failure or heart attack, angina, and
diabetic neuropathy.
Besides this, L-Carnitine acts as an antioxidant that rules out
harmful free radicals from body, which otherwise can lead to severe
cell damage.
The L-Carnitine market has been segmented into Germany, the UK, France, Italy, Spain,
and Rest of Europe.Germany held the largest share of the European
L-Carnitine market, followed by France and the UK.
The growing focus on health-promoting food products is one of the
key factors boosting the L-Carnitine market. The presence of
several manufacturers such as ChengDa Pharmaceuticals Co., Ltd;
Maxsun Industries Incorporated; Alpsure Lifesciences Pvt. Ltd;
Lonza Group Ltd; Northeast Pharmaceutical Group Co., Ltd; Merck
KGaA; and Biosint S.p.A., has bolstered the growth of the
L-Carnitine market. Also, the consumer demand for healthy and
nutritious products without any compromise on taste is expected to
propel the growth of the L-Carnitine market in the region. Further,
the growth of healthcare, food processing, and other industries is
boosting the demand for L-Carnitine in this region.
Impact of COVID-19 Pandemic on L-Carnitine Market
The recent COVID-19 outbreak began in Wuhan (China)
in December 2019, and since then it
has spread across the globe at a fast pace.China, Italy, Iran,
Spain, the Republic of Korea,
France, Germany, and the US are among the worst
affected countries in terms confirmed cases and reported deaths as
of March 2020.
The COVID-19 outbreak has affected economies and industries in
various countries due to lockdowns, travel bans, and business
shutdowns. The overall dip in the global market due to COVID-19 is
also affecting the growth of the L-Carnitine market due to factory
shutdowns, supply chain discontinuation, and economic
downturns.
ChengDa PharmaCeuticals Co., Ltd; Maxsun Industries Incorporated;
Alpsure Lifesciences Pvt. Ltd; Lonza Group Ltd; Northeast
Pharmaceutical Group Co., Ltd; Merck KGaA; and Biosint S.p.A., are
among the major players in the European L-Carnitine market.
The overall Europe L-Carnitine market size has been derived in
accordance to both primary and secondary sources.To begin the
research process, exhaustive secondary research has been conducted
using internal and external sources to obtain qualitative and
quantitative information related to the market.
Also, multiple primary interviews have been conducted with industry
participants and commentators to validate the data, as well as to
gain more analytical insights into the topic. The participants who
typically take part in such a process include industry expert such
as VPs, business development managers, market intelligence
managers, and national sales managers along with external
consultants such as valuation experts, research analysts, and key
opinion leaders specializing in the L-Carnitine market.
Read the full report:
https://www.reportlinker.com/p05894542/?utm_source=PRN
About Reportlinker
ReportLinker is an award-winning market research solution.
Reportlinker finds and organizes the latest industry data so you
get all the market research you need - instantly, in one place.
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001
View original
content:http://www.prnewswire.com/news-releases/the-l-carnitine-market-was-valued-at-us-47-1-million-in-2018-and-is-projected-to-reach-us-72-7-million-by-2027-it-is-expected-to-grow-at-a-cagr-of-4-9-from-2019-to-2027--301064562.html
SOURCE Reportlinker